Thelansis

Systemic Scleroderma Market Outlook Thelansis’s “Systemic Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? W...

Systemic Scleroderma Market Outlook Thelansis’s “Systemic Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Systemic Scleroderma Overview Scleroderma, or Systemic sclerosis (SS), is a connective tissue disorder primarily marked by skin thickening and hardening. It comes in two main forms: localized and systemic. Localized scleroderma primarily affects the skin, possibly involving muscles and bones. On the other hand, systemic scleroderma impacts internal organs like the digestive tract, heart, lungs, and kidneys. The condition’s severity and outcome ...

 Scleroderma or Systemic sclerosis (SS), is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. There are two primary types of scleroderma: localized and systemic. In localized scleroderma, the disease mainly affects the skin and may impact the muscles and bones. In systemic scleroderma, there is an involvement of the internal organs, such as the digestive tract, heart, lungs, and kidneys, among others. The severity and outcome of scleroderma are variable. Genetic and environmental factors play a role in the genesis of scleroderma. Silica and certain organic solvents are recognized as risk factors for the occurrence of systemic scleroderma. Life expectancy in patients with systemic sclerosis depends on the extent and severity of internal organ involvement. During SSc, the death rate is 3.5 times higher than healthy subjects of the same age. The overall survival of patients with SSc ranges from 75 to 80% after five years, 55% after ten y...